Neuromyelitis Optica Spectrum Disorder Clinical Trial
Official title:
Effectiveness and Safety of Inebilizumab in the Acute Phase of Neuromyelitis Optica Spectrum Disorders-a Multicentric, Prospective, Real Word Study
This study is aimed to observe the effectiveness and safety of inebilizumab in the acute phase of neuromyelitis optica spectrum disorders.
Status | Not yet recruiting |
Enrollment | 50 |
Est. completion date | July 31, 2025 |
Est. primary completion date | July 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 1. Age = 18 years with anti-AQP4-IgG seropositive NMOSD as defined by 2015 NMOSD diagnostic criteria by IPND (International Panel for NMO Diagnosis); 2. In the acute phase of NMOSD (definition of acute phase: new neurological symptoms or aggravation of existing symptoms within 30 days before screening, lasting at least 24 hours without with fever); 3. Patients who plan to receive or are receiving intravenous methylprednisolone therapy; 4. Expanded disability status scale (EDSS) score = 8 and = 2.5 during the screening period; 5. Able and willing to give written informed consent; 6. Women of childbearing potential who agree to use adequate contraception during the study. Exclusion Criteria: - 1. Lactating and pregnant females; 2. Participate in other interventional studies within 30 days before screening or within 5 half-lives of the investigational agent before enrollment; 3. Combined with severe mental disorders and other conditions and unable to cooperate with follow-up; 4. History of malignancies; 5. Received plasma exchange, immunoadsorption or intravenous immunoglobulin therapy within 1 month before screening; 6. Patients with negative hepatitis B surface antibody (HBsAg) and positive hepatitis B core antibody (HBcAb), or HBsAg-positive virus carriers, or patients with active tuberculosis or positive tuberculosis screening without appropriate treatment history; 7. Other situations that researchers think are not suitable to participate in this study. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Xuanwu Hospital, Beijing |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Expanded Disability Status Scale (EDSS) score from baseline | Change in Expanded Disability Status Scale (EDSS) score from baseline at the last visit(EDSS : Minimum Score 1, Maximum score 10, higher scores mean a worse outcome). | 6 months | |
Secondary | Change in Expanded Disability Status Scale (EDSS) score from baseline | Change in Expanded Disability Status Scale (EDSS) score from baseline at month 1, month 3(EDSS : Minimum Score 1, Maximum score 10, higher scores mean a worse outcome). | 1 months, 3 months | |
Secondary | Percentage of Participants With Disability Improvement | Disability improvement is defined as a reduction in EDSS score of: A) >=1.0 from the baseline EDSS score when the baseline score was <=5.5 B) >= 0.5 when the baseline EDSS score > 5.5(EDSS : Minimum Score 1, Maximum score 10, higher scores mean a worse outcome). | 6 months | |
Secondary | Change in modified Rankin score (mRS) from baseline | Change in modified Rankin score (mRS) from baseline at month 1, month 3, month 6(mRS : Minimum Score 0, Maximum score 6, higher scores mean a worse outcome). | 1 months, 3 months, 6 months | |
Secondary | Time to first relapse | 6 months | ||
Secondary | Number of New, and/or Enlarging T2 Hyperintense Lesions Detected by Magnetic Resonance Imaging (MRI) | Number of New, and/or Enlarging T2 Hyperintense Lesions Detected by Magnetic Resonance Imaging (MRI) at the last visit | 6 months | |
Secondary | Change in Timed 25 Foot Walk Test from baseline | Change in time taken to complete the timed 25 foot walk test from baseline | 1 months, 3 months , 6 months | |
Secondary | Number of NMOSD attacked related rescue treatment | 6 months | ||
Secondary | Change in serum GFAP levels from baseline | Change in serum GFAP levels from baseline at the last visit | 6 months | |
Secondary | Change in AQP4-ab titers from baseline | Change in AQP4-ab titers from baseline at the last visit | 6 months | |
Secondary | Change in Low-contrast Visual Acuity (LCVA) from baseline | Change in Low-contrast Visual Acuity (LCVA) at month 3, month 6)(The LCVA test is used to determine the number of letters that can be read on a standardized low-contrast Landolt C Broken Rings Chart held at a distance of 3 meters). | 3 months, 6 months | |
Secondary | Changes in EQ-5D-5L scores from baseline | Changes in EQ-5D scores from baseline at month 1 month, month 3 , month 6(EQ-5D-5L: Minimum Score 5, Maximum score 25, lower scores mean a better quality of life). | 1 month, 3 months ,6 months | |
Secondary | Change in retinal nerve fiber layer (RNFL) loss from baseline | Change in retinal nerve fiber layer (RNFL) loss measured by optical coherence tomography (OCT) from baseline at month 1, month 3,month 6. | 3 months ,6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
Completed |
NCT03002038 -
Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04064944 -
Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders
|
Phase 2 | |
Recruiting |
NCT05414487 -
Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases
|
||
Not yet recruiting |
NCT05551598 -
Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
Phase 2 | |
Recruiting |
NCT05403138 -
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
|
Phase 2/Phase 3 | |
Completed |
NCT01845584 -
Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
|
Phase 2 | |
Completed |
NCT04660539 -
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
Phase 3 | |
Recruiting |
NCT05199688 -
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
Phase 3 | |
Recruiting |
NCT05504694 -
Ofatumumab in AQP4-IgG Seropositive NMOSD
|
Phase 1/Phase 2 | |
Recruiting |
NCT05346354 -
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
|
Phase 2/Phase 3 | |
Completed |
NCT01777412 -
Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
|
Phase 1 | |
Recruiting |
NCT01623076 -
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
|
||
Completed |
NCT01500681 -
Maintenance Plasma Exchange for Neuromyelitis Optica
|
||
Not yet recruiting |
NCT06374264 -
Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder
|
N/A | |
Recruiting |
NCT05909761 -
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
|
||
Completed |
NCT02276963 -
Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
|
Phase 1 | |
Terminated |
NCT04155424 -
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
|
Phase 2/Phase 3 | |
Completed |
NCT02003144 -
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
|
Phase 3 | |
Completed |
NCT03819413 -
Clinical Patterns of Neuromyelitis Optica Spectrum Disorders in Assiut University Hospital
|